Nusinersen

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infantile-onset Spinal Muscular Atrophy

Conditions

Infantile-onset Spinal Muscular Atrophy

Trial Timeline

— → —

NCT ID

NCT02865109

About Nusinersen

Nusinersen is a pre-clinical stage product being developed by Biogen for Infantile-onset Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT02865109. Target conditions include Infantile-onset Spinal Muscular Atrophy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02865109	Pre-clinical	Completed	—	—	Infantile-onset Spinal Muscular Atrophy
NCT06555419	Phase 1	Recruiting	Jan 16, 2025	Jun 25, 2027	Muscular Atrophy, Spinal
NCT05067790	Phase 3	Active	Jan 21, 2022	Jun 14, 2027	Spinal Muscular Atrophy
NCT04729907	Phase 3	Active	Apr 19, 2021	Jul 31, 2026	Muscular Atrophy, Spinal
NCT04488133	Approved	Completed	Jan 4, 2021	Oct 9, 2025	Muscular Atrophy, Spinal
NCT04089566	Phase 3	Completed	Mar 26, 2020	May 30, 2024	Muscular Atrophy, Spinal
NCT04591678	Pre-clinical	Completed	Oct 1, 2018	Jun 25, 2021	Spinal Muscular Atrophy
NCT02594124	Phase 3	Completed	Nov 4, 2015	Aug 21, 2023	Spinal Muscular Atrophy
NCT02462759	Phase 2	Terminated	Aug 19, 2015	Sep 24, 2018	Spinal Muscular Atrophy
NCT02386553	Phase 2	Completed	May 18, 2015	Dec 17, 2024	Spinal Muscular Atrophy
NCT02292537	Phase 3	Completed	Nov 24, 2014	Feb 20, 2017	Spinal Muscular Atrophy
NCT02193074	Phase 3	Terminated	Aug 19, 2014	Nov 21, 2016	Spinal Muscular Atrophy
NCT02052791	Phase 1	Completed	Jan 31, 2014	Jan 31, 2017	Spinal Muscular Atrophy
NCT01839656	Phase 2	Completed	May 8, 2013	Aug 21, 2017	Spinal Muscular Atrophy
NCT01780246	Phase 1	Completed	Jan 31, 2013	Feb 28, 2014	Spinal Muscular Atrophy
NCT01703988	Phase 1/2	Completed	Oct 31, 2012	Jan 31, 2015	Spinal Muscular Atrophy
NCT01494701	Phase 1	Completed	Nov 30, 2011	Jan 31, 2013	Spinal Muscular Atrophy

Competing Products

3 competing products in Infantile-onset Spinal Muscular Atrophy

See all competitors

Product	Company	Stage	Hype Score
alglucosidase alfa + alglucosidase alfa	Sanofi	Approved	84
Myozyme	Sanofi	Phase 2	51
ATB200 + AT2221	Amicus Therapeutics	Pre-clinical	20

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved